William Mack & Associates
AZN icon

William Mack & Associates’s AstraZeneca AZN Stock Holding History

William Mack & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$76.1K Buy
+471
New +$78.5K 0.02% 199

Other funds holding AZN

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $162B AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

William Mack & Associates's AZN Position: Q3 2026 in Review

William Mack & Associates opened a new position in AstraZeneca (AZN) in Q3 2026: 471 shares worth $76.1K. The stake represents 0.02% of the portfolio and ranks #199 among its holdings.

1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • William Mack & Associates held 471 shares of AstraZeneca worth $76.1K as of Q3 2026.
  • AstraZeneca was a new William Mack & Associates position in Q3 2026.
  • AstraZeneca made up 0.02% of William Mack & Associates's portfolio in Q3 2026, its #199 holding.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.